Funder
National Institutes of Health
Melanoma Research Alliance
Irving Medical Center, Columbia University
Swim Across America
Howard Hughes Medical Institute
Publisher
Springer Science and Business Media LLC
Subject
Dermatology,General Medicine
Reference134 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
2. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
3. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.
4. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32.
5. US Food and Drug Administration. FDA approves pembrolizumab for adjuvant treatment of melanoma. FDA: Maryland; 2019.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献